Resetting the Immune System with TCR-engineered Autologous Tregs for Tissue Specific Tolerance Induction

Time: 5:15 pm
day: Conference Day One


  • Testing the therapeutic potential of TCR-engineered autoantigen specific Tregs to reset immune tolerance to treat progressive-MS or T1D
  • Defining drivers of tissue residency and durability of TCR-engineered Tregs
  • Measuring long lasting tolerance induction; considerations of clinical trial length